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Abstract
The ATP-binding cassette transporter protein, multidrug resistance protein MRP1, was purified from doxorubicin-selected
H69AR lung tumor cells which express high levels of this protein. A purification procedure comprised of a differential two-
step solubilization of MRP1 from plasma membranes with 3-(3-cholamidopropyl)dimethylammonio-1-propanesulfonate
followed by immunoaffinity chromatography using the MRP1-specific monoclonal antibody QCRL-1 was developed.
Approximately 300 Wg of MRP1 was obtained from 6 mg of plasma membranes at 80^90% purity, as indicated by silver
staining of protein gels. After reconstitution of purified MRP1 into proteoliposomes, kinetic analyses indicated that its Km
for ATP hydrolysis was 104 þ 22 WM with maximal activity of 5^10 nmol min31 mg31 MRP1. MRP1 ATPase activity was
further characterized with various inhibitors and exhibited an inhibition profile that distinguishes it from P-glycoprotein and
other ATPases. The ATPase activity of reconstituted MRP1 was stimulated by the conjugated organic anion substrates
leukotriene C4 (LTC4) and 17L-estradiol 17-(L-D-glucuronide) with 50% maximal stimulation achieved at concentrations of
150 nM and 1.6 WM, respectively. MRP1 ATPase was also stimulated by glutathione disulfide but not by reduced glutathione
or unconjugated chemotherapeutic agents. This purification and reconstitution procedure is the first to be described in which
the ATPase activity of the reconstituted MRP1 retains kinetic characteristics with respect to ATP-dependence and substrate
stimulation that are very similar to those deduced from transport studies using MRP1-enriched plasma membrane
vesicles. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Multidrug resistance protein MRP1 is a 190-kDa
plasma membrane protein that confers multidrug re-
sistance on cells in which it is overexpressed [1^3].
Since its cDNA was cloned from the doxorubicin-
selected human small cell lung cancer cell line,
H69AR [4], MRP1 expression has been detected in
many di¡erent drug resistant cell lines and in a range
of both hematologic and solid tumors [5^8]. In some
cases, MRP1 expression has been correlated with
clinical outcome [6,7]. MRP1, like the well charac-
terized multidrug resistance protein P-glycoprotein,
belongs to the large and ancient ATP-binding cas-
sette (ABC) or tra⁄c-ATPase superfamily of mem-
brane transport proteins [9]. However, MRP1 and P-
glycoprotein share rather limited sequence similarity
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(6 20%), which is largely con¢ned to the generally
conserved nucleotide binding domains (NBDs) com-
mon to all ABC proteins [3,4]. In addition, MRP1
and several of its most closely related proteins are
atypical ABC proteins in that they contain an extra,
third membrane spanning domain with an extra-
cytosolic NH2-terminus [2,3,10]. Conserved features
of protein structure and gene organization suggest
that, unlike P-glycoprotein, MRP1 and related
proteins share a common ancestry with the cystic
¢brosis transmembrane conductance regulator
(CFTR) [2^4].
The function of MRP1 as an ATP-dependent
transporter has been studied extensively using mem-
brane vesicles prepared from drug-selected and trans-
fected cells which overexpress the protein. These in-
vestigations have shown that vesicles enriched in
MRP1 display ATP-dependent, high a⁄nity trans-
port of the cysteinyl leukotriene LTC4 and other
glutathione (GSH) conjugated organic anions as
well as oxidized glutathione (GSSG) [11^17]. In ad-
dition, an estradiol metabolite formed in the liver,
17L-estradiol 17-(L-D-glucuronide) (E217LG), has
been shown to be a substrate of MRP1 [18,19].
Thus, MRP1 has been demonstrated to be a primary
active transporter of structurally diverse conjugated
organic anions. In contrast, it has not been possible
to detect direct active transport of chemotherapeutic
agents by MRP1-enriched membrane vesicles under
similar conditions [14,16,20]. However, MRP1-de-
pendent active transport of certain unconjugated
xenobiotics such as vincristine, daunorubicin and
a£atoxin B1 is observed if vesicle preparations are
supplemented with physiological concentrations of
GSH [14,15,21]. More recent studies suggest that
MRP1 actively co-transports some unmodi¢ed sub-
strates together with GSH [20,22].
The mechanism by which MRP1 transports con-
jugated organic anions and unmodi¢ed xenobiotics
has yet to be elucidated. However, it is presumed
that, like P-glycoprotein, MRP1 functions as an en-
ergy-dependent e¥ux pump driven by the hydrolysis
of ATP. High levels of drug-stimulated ATPase ac-
tivity have been reported for plasma membrane
vesicles enriched in P-glycoprotein [23,24], as well
as the puri¢ed and reconstituted protein [25^28]. In
contrast, studies with MRP1-enriched plasma mem-
brane vesicles have suggested that the constitutive
and substrate-stimulated ATPase activity of MRP1
is considerably lower than that observed for P-glyco-
protein [29] (unpublished observations). However,
characterization of the ATPase activity of MRP1 in
such preparations has been complicated by other en-
dogenous ATPases which are often present at very
high levels [29] (unpublished observations). Conse-
quently, to investigate the relationship between
drug transport, ATP binding and hydrolysis, puri¢-
cation of functional MRP1 is essential. In the present
study, we describe a simple immunoa⁄nity puri¢ca-
tion procedure for native MRP1 from the mem-
branes of multidrug resistant H69AR cells. We also
show that when reconstituted into liposomes, MRP1
has low level constitutive ATPase activity that has
broad nucleotide speci¢city and can be stimulated
by conjugated organic anions. Inhibitor studies
with various inhibitors indicate that the ATPase ac-
tivity of MRP1 is distinct from that of typical P-, F-,
and V-type ATPases as well as P-glycoprotein.
2. Materials and methods
2.1. Materials
E217LG, 17L-estradiol 3-(L-D-glucuronide), GSH,
GSSG, S-decyl GSH, ATP, AMP, sodium ortho-
vanadate, 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole
(NBD-C1), EGTA, ba¢lomycin A1, oligomycin and
all nucleotides were purchased from Sigma (St.
Louis, MO, USA). LTC4 was from Calbiochem
(La Jolla, CA, USA). Dithiothreitol (DTT) and 2-
mercaptoethanol were purchased from Fisher Scien-
ti¢c (Fair Lawn, NJ, USA). NaF and ouabain were
from ICN (Aurora, OH, USA). NaN3 was from
BDH Chemicals (Toronto, Ont., USA). N-Ethylma-
leimide (NEM) was from Aldrich (Milwaukee, WI,
USA). All of the above compounds were dissolved in
distilled water and the solutions were neutralized to
pH 7.5 with 1 M Tris base. The vanadate solution
was boiled 10 min and then chilled on ice before use.
CHAPS and n-octyl-L-D-glucopyranoside were from
ICN. The human MRP1-speci¢c murine IgG1 mAb
QCRL-1 has been characterized previously [30,31].
The hexapeptide SSYSGDI corresponding to the
QCRL-1 epitope was synthesized by Research Genet-
ics (Huntsville, AL, USA).
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2.2. Cell culture and plasma membrane preparation
The small cell lung cancer cell line H69 and its
doxorubicin-selected multidrug resistant variant,
H69AR, have been described previously [4,32]. Cells
were grown as suspension cultures in 500 ml glass
bottles in RPMI 1640 medium containing 5% de¢ned
bovine calf serum (HyClone Laboratories, Logan,
UT, USA) in the absence of antibiotics.
Plasma membranes were prepared essentially as
described [14]. Brie£y, 1 g of wet cells (approximately
108 H69AR cells) stored at 380‡C was thawed in
30 ml homogenization bu¡er containing 10 mM
Tris-HCl, pH 7.5, 250 mM sucrose, 3 mM KCl,
0.25 mM MgCl2 and protease inhibitors. The cells
were broken by N2 cavitation (10 min equilibrium
at 175 psi) and EDTA was added to 1 mM. Cell
debris was removed by low speed centrifugation
(500Ug, 15 min) and the pellet was washed once
with 10 ml of homogenization bu¡er. Pooled super-
natants were layered over 35% sucrose (10 ml) in
bu¡er containing 10 mM Tris-HCl, pH 7.5, 1 mM
EDTA and centrifuged at 100 000Ug for 1.5 h at
4‡C. Material at the interface was recovered, pelleted
by centrifugation (100 000Ug, 1 h at 4‡C) and then
resuspended in storage bu¡er containing 50 mM
Tris-HCl, pH 7.5 and 250 mM sucrose. The mem-
brane suspension was passed ¢ve times through a
27.5-gauge needle and then stored at 380‡C until
use. The protein concentration of the plasma mem-
brane preparation was typically 2^4 mg ml31.
2.3. Solubilization of MRP1
Plasma membranes (5 mg isolated from approxi-
mately 1 g of wet H69AR cells) were thawed and
centrifuged at 100 000Ug for 15 min at 4‡C. The
pellet was resuspended in 0.5 ml of bu¡er A contain-
ing 50 mM Tris-HCl, pH 7.4, 150 mM NH4Cl,
1 mM EDTA and 5 mM CHAPS. The ¢nal protein
concentration was approximately 10 mg ml31. The
mixture was incubated on ice for 30 min with gentle
magnetic stirring and centrifuged at 100 000Ug for
15 min at 4‡C. The pellet was washed once with
0.5 ml of bu¡er B containing 50 mM Tris-HCl, pH
7.4, 10% glycerol (w:v), 0.15 M NaCl and 1 mM
EDTA. The washed pellet was resuspended in 5 ml
of bu¡er B containing 10 mM CHAPS and incu-
bated on ice for 30 min with gentle magnetic stirring
to solubilize MRP1. The sample was then pelleted at
100 000Ug for 15 min at 4‡C. The resulting super-
natant was immediately subjected to immunoa⁄nity
chromatography.
2.4. Puri¢cation of mAb QCRL-1
GammaBind Plus Sepharose resin (Pharmacia Bio-
tech) (1 ml) was packed in a spin column, then
washed ¢ve times with 5 ml 0.1 M glycine-HCl, pH
2.7 and equilibrated with 20 mM sodium phosphate
bu¡er, pH 7.0 by a similar washing procedure
(100Ug, 30 s, 4‡C). Mouse ascites £uid containing
mAb QCRL-1 was then mixed with the pre-equili-
brated resin and gently shaken for 1 h at room tem-
perature. The resin with bound antibody was washed
¢ve times with 10 ml of 20 mM sodium phos-
phate bu¡er, pH 7.0. mAb QCRL-1 was then
eluted by washing six times with 1 ml of 0.1 M
glycine-HCl, pH 2.7 and immediately neutralized
with 1 M Tris base. The puri¢ed mAb was stored
at 4‡C.
2.5. Preparation of mAb QCRL-1 immunoa⁄nity
column
The glycine bu¡er in the preparations of puri¢ed
mAb QCRL-1 was exchanged with coupling bu¡er
(0.1 M NaHCO3, 0.5 M NaCl, pH 8.3) by dialysis
overnight at 4‡C. Puri¢ed mAb QCRL-1 (5 mg) in
coupling bu¡er was then incubated with 1 g of swol-
len CNBr-activated Sepharose 4B resin (Pharmacia)
that had been pre-washed with 1 mM HCl (200 ml).
After incubation with gentle shaking overnight at
4‡C in a 15 ml spin column (Bio-Rad), unbound
antibody was washed away by brief centrifugation
(30 s, 100Ug) with ¢ve times the gel volume of cou-
pling bu¡er (5U3 ml). Tris-HCl bu¡er (0.1 M Tris-
HCl, pH 8.0) (5 ml) was added to the column and
incubation with gentle shaking continued for 2 h at
room temperature to block the remaining active
groups. The column was then washed with 10 ml
of bu¡er containing 0.1 M sodium acetate, pH 4.0,
0.5 M NaCl, followed by 10 ml of 0.1 M Tris-HCl,
pH 7.5, 0.5 M NaCl. The column was stored at 4‡C
in Tris bu¡er supplemented with 0.02% NaN3 until
use.
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2.6. Immunoa⁄nity chromatography of MRP1
All immunoa⁄nity puri¢cation steps were carried
out on ice or at 4‡C. The spin column containing
3 ml of Sepharose resin coupled to mAb QCRL-1
was washed four times with 5 ml of glycine bu¡er
(0.1 M glycine, pH 2.7) and then equilibrated by a
similar washing procedure with bu¡er C containing
50 mM Tris-HCl, pH 7.4, 1 mM EDTA, 20% glyc-
erol, 0.5 M NaCl, 5 mM CHAPS, all by brief cen-
trifugation (30 s, 100Ug, each time). Solubilized
MRP1 (5 ml) was then mixed with the equilibrated
resin and incubated for 3 h with gentle shaking. The
resin with bound protein was washed 10 times with
5 ml of bu¡er C as above. A heptapeptide (10 mg)
corresponding to the QCRL-1 epitope (SSYSGDI)
[31] was dissolved in bu¡er C and mixed with the
resin and the mixture was then incubated overnight
at 4‡C with gentle shaking. The ¢nal QCRL-1 pep-
tide concentration was approximately 3.3 mg ml31.
MRP1 was eluted by brief centrifugation (30 s,
100Ug) and the resin washed ¢ve times with 2 ml
of bu¡er C without peptide. The eluant and washes
were pooled and the MRP1 immediately reconsti-
tuted (see below). The immunoa⁄nity column was
regenerated by washing with 25 ml of 0.1 M sodium
acetate, pH 4.0, 25 ml of 0.1 M glycine, pH 2.7,
25 ml of bu¡er C supplemented with 0.02% NaN3
and stored at 4‡C. The column could be re-used up
to 10 times.
2.7. Reconstitution of the puri¢ed MRP1 into
proteoliposomes
Liposome preparations were made as follows. Bo-
vine brain lipid extract containing a minimum of
40% phosphatidylethanolamine (Sigma, brain ex-
tract, Type V) and cholesterol were resuspended in
a ratio of 80:20 (w:w) in reconstitution bu¡er
(50 mM Tris-HCl, pH 7.4, 0.15 M NaCl, 1 mM
DTT, 1 mM MgCl2) at a concentration of 20 mg
ml31. The lipid suspension was sonicated for 30 min
at room temperature under argon and then frozen-
thawed ¢ve times in liquid N2 followed by sonication
for 60 s. The liposomes were stored in aliquots at
370‡C. Before use, the liposomes were again fro-
zen-thawed ¢ve times followed by sonication for
60 s. For reconstitution, 0.03 mg of puri¢ed MRP1
was mixed with 1.2 mg of sonicated liposomes in a
0.75 ml volume of bu¡er containing 50 mM Tris-
HCl, pH 7.4, 0.15 M NaCl, 1 mM DTT, 1 mM
MgCl2, 60 mM n-octyl-L-D-glucopyranoside and
3.7 mM CHAPS. The mixture was incubated on ice
for 1 h and diluted 25-fold into reconstitution bu¡er.
The diluted sample was again incubated for 45 min
at 4‡C and proteoliposomes were then harvested by
centrifugation at 145 000Ug for 1 h at 4‡C. The pel-
let was resuspended in 0.1 ml of storage bu¡er
(50 mM Tris-HCl, pH 7.5, 250 mM sucrose) and
passed ¢ve times through a 27.5-gauge needle. The
proteoliposomes were aliquoted and stored at 370‡C
until use. In a typical experiment, recovery of MRP1
in the proteoliposomes was 20^30%.
2.8. SDS-Polyacrylamide gel electrophoresis
(SDS-PAGE), silver staining and
immunoblotting
Gel electrophoresis was carried out using 7.5%
SDS-polyacrylamide minigels in a Bio-Rad Mini-
Protean II electrophoresis cell. Proteins were stained
with alkaline silver [33]. For immunoblotting, pro-
teins were transferred to Immuno-P membranes
(Millipore, Bedford, MA, USA) using 25 mM Tris,
192 mM glycine and 20% methanol bu¡er. Blots
were blocked in TBS-T bu¡er (10 mM Tris-HCl,
0.15 mM NaCl, 0.05% Tween 20, pH 7.5) with 5%
skim milk for 1 h at room temperature. The blot was
incubated with mAb QCRL-1 ascites (diluted
1:10 000) followed by goat anti-mouse IgG+IgM
(H+L) horseradish peroxidase-conjugated F(ab’)2
fragment (diluted 1:5000) (Pierce, Rockford, IL,
USA). The blots were developed using a chemilumi-
nescence detection kit (Boehringer Mannheim, Laval,
Que., Canada). Protein concentrations were deter-
mined using a modi¢ed Lowry assay [34] and bovine
serum albumin as standard.
2.9. Assay of ATPase activity
To measure ATPase activity, puri¢ed and recon-
stituted MRP1 (0.5^1.5 Wg) was incubated at 37‡C in
0.1 ml of bu¡er containing 50 mM Tris-HCl, pH 7.4,
5 mM MgCl2 for 4 h. The ATP concentration used
was 2.5 mM and the pH of the assay bu¡er was 7.4
unless otherwise indicated. Reactions were stopped
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by the addition of 33.3 Wl of 18% SDS and the
amount of inorganic phosphate released was deter-
mined immediately as described [35,36]. In control
reactions, 33.3 Wl of 18% SDS was included in the
assay bu¡er before MRP1 was added to ensure that
MRP1 was inactivated. The added substrates, GSH,
inhibitors and drugs did not contribute to the color
reaction in the control incubations. To determine the
e¡ect of pH on MRP1 ATPase activity, assays were
carried out at pH 4.0^9.5 using 50 mM Tris-HC1
bu¡ers to maintain pH 6.5^9.5 and 50 mM sodium
acetate bu¡ers to maintain pH 4.0^5.5.
2.10. MRP1-mediated transport of LTC4 in
membrane vesicles
Inside-out membrane vesicles used for transport
assays were isolated from MRP1-transfected HeLa
T5 cells and MRP1-mediated ATP-dependent trans-
port of [3H]LTC4 into the membrane vesicles was
measured by rapid ¢ltration essentially as described
[14]. To measure the e¡ect of pH on MRP1 transport
activity, assays were carried out at pH 5^9 using
Tris-HC1 bu¡ers (50 mM) to maintain pH 6.5^9.0
and sodium acetate bu¡ers (50 mM) to maintain pH
5^6.
3. Results
3.1. Puri¢cation and reconstitution of MRP1 from
H69AR plasma membranes
Approximately 5 mg of plasma membranes were
isolated from 1U108 H69AR cells by a sucrose den-
sity centrifugation procedure. To extract MRP1 from
plasma membranes, we used a di¡erential detergent
solubilization procedure similar to that used previ-
ously to solubilize P-glycoprotein [36]. Treatment of
H69AR plasma membranes at a protein concentra-
tion of 10 mg ml31 with a bu¡er containing 5 mM
CHAPS solubilized approximately 40% of total pro-
tein while more than 90% of the MRP1 remained in
an insoluble fraction that could be recovered by cen-
trifugation. However, when the CHAPS concentra-
tion was increased to 10 mM, nearly 50% of MRP1
was solubilized. Based on these observations, 5 mM
CHAPS and 10 mg ml31 of plasma membranes were
routinely used in the ¢rst detergent solubilization
step. In the second step, the pellet from the ¢rst
CHAPS extraction was resuspended at a protein con-
centration of approximately 0.5 mg ml31 in bu¡ers
containing various concentrations of CHAPS. At
5 mM CHAPS, approximately one-third of MRP1
Fig. 1. Analysis of MRP1 at each stage of puri¢cation and after reconstitution into proteoliposomes. (A) Proteins were subjected to
SDS-PAGE and detected by silver staining. (B) Immunoblot of the protein gel shown in Panel A with mAb QCRL-1. Lane 1, plasma
membranes, 10 Wg protein; lane 2, membrane proteins solubilized with 10 mM CHAPS, 5 Wg protein; lane 3, native MRP1 puri¢ed
by immunoa⁄nity chromatography, 1 Wg protein; lane 4, reconstituted MRP1 proteoliposomes, 0.4 Wg protein.
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was solubilized while at 10 mM CHAPS, over 90% of
MRP1 and approximately 50% of total protein could
be recovered in the supernatant. Thus, we routinely
used 10 mM CHAPS and a protein concentration of
0.5 mg ml31 in the second extraction step. Based on
densitometry, MRP1 comprised 20^30% of total
membrane proteins in the second CHAPS extract
(Fig. 1A).
A number of conventional chromatography proce-
dures were investigated for further puri¢cation in-
cluding ion-exchange, gel ¢ltration, hydroxyapatite,
Con A a⁄nity Sepharose and isoelectric focusing.
However, all were found to be relatively ine¡ective
because of either poor yield or failure to increase
purity. As an alternative approach, we investigated
the use of immunoa⁄nity chromatography with the
MRP1-speci¢c mAb QCRL-1. The MRP1 CHAPS
extract was concentrated to 5 ml and mixed with
MAb QCRL-1 Sepharose resin (V3 ml) and over
90% of MRP1 was bound to the resin after incuba-
tion at 4‡C for 3 h. Incubation of the immunoa⁄nity
resin overnight at 4‡C with the synthetic peptide
SSYSGDI (which corresponds to the epitope of
mAb QCRL-1) [31] resulted in elution of approxi-
mately 90% of the bound MRP1. The MRP1 recov-
ered was approximately 80% pure, as judged by den-
sitometry of a silver-stained SDS-PAGE gel (Fig.
1A). With this approach, approximately 300 Wg of
MRP1 could be puri¢ed from 6 mg of H69AR plas-
ma membranes. Based on densitometry of immuno-
blots using puri¢ed MRP1 as a standard, MRP1 ac-
counts for approximately 5^6% of total plasma
membrane proteins in the multidrug resistant
H69AR cells (not shown). Thus the overall recovery
following solubilization and puri¢cation was greater
than 80%, since 6 mg of plasma membranes would
be predicted to contain approximately 300 Wg of
MRP1.
Proteoliposomes were formed by rapid dilution of
the puri¢ed MRP1 into a detergent-free bu¡er. Bo-
vine brain lipids were used in approximately 10 000-
fold molar excess to MRP1, assuming an average
lipid molecular weight of 700 Da. Because cholester-
ol has been shown to enhance ATP-dependent sub-
strate transport mediated by solubilized hepatocyte
canalicular membranes in a reconstituted system
[37], we routinely supplemented the bovine brain lip-
ids with 20% cholesterol. Typically, 20^30% of
MRP1 could be recovered in proteoliposome prepa-
rations isolated by ultracentrifugation. A silver-
stained gel of such MRP1 proteoliposome prepara-
tions is shown in Fig. 1A. An immunoblot of the
various MRP1 preparations is shown in Fig. 1B.
Vesicles containing puri¢ed MRP1 were stained
with uranyl acetate and determined to have diame-
ters of approximately 200 nm by electron microscopy
(not shown).
Fig. 2. Basal ATPase activity of puri¢ed and reconstituted
MRP1. (A) ATP hydrolysis activity exhibited by increasing
amounts of puri¢ed native MRP1 in assay bu¡er containing 0.9
mM CHAPS (8) or puri¢ed MRP1 reconstituted in liposomes
(F). The ATPase activity was assayed in a reaction mixture
containing 50 mM Tris-HCl, pH 7.4, 5 mM ATP, 5 mM
MgCl2 and incubated for 4 h at 37‡C. (B) The time dependence
of ATPase activity exhibited by proteoliposomes containing 0.6
Wg of puri¢ed MRP1 in a total volume of 10 Wl was as de-
scribed in Panel A. Data points represent mean values ( þ S.E.)
of three independent determinations.
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3.2. ATPase activity of puri¢ed and reconstituted
MRP1
The ATPase activity of MRP1 solubilized in
CHAPS was V1.5 nmol min31 mg31 which is ap-
proximately ¢ve-fold lower than that of MRP1 in
reconstituted proteoliposomes (Fig. 2A), suggesting
that, like many other membrane proteins, MRP1
requires a lipid environment for optimal activity.
Reconstituted MRP1 proteoliposomes exhibited
ATPase activity proportional to the amount of in-
corporated puri¢ed MRP1 protein (Fig. 2A). The
ATPase activity of reconstituted MRP1 was linear
with respect to time for up to 4 h at 37‡C (Fig.
2B) and exhibited a Km (ATP) of 104 þ 22 WM, as
determined by Lineweaver-Burk plot analysis (Fig.
3). The speci¢c ATPase activity of MRP1 varied
somewhat from batch to batch but was typically 5^
10 nmol min31 mg31 MRP1. As controls, mem-
branes from drug sensitive H69 and revertant
H69PR cells which have levels of MRP1 that are
100- and 25-fold lower than the drug resistant
H69AR cells, respectively, were subjected to the
same protein puri¢cation and reconstitution proce-
dures. No ATPase activity was detected in proteoli-
posomes prepared from the H69 or H69PR eluates
of the QCRL-1 a⁄nity resin (results not shown).
Occasionally, the ATPase activity of MRP1 could
be stimulated slightly by DTT and 2-mercaptoetha-
nol, suggesting that oxidation during the immunoaf-
¢nity puri¢cation and reconstitution procedures and/
or the relatively long incubation period could be del-
eterious to the ATPase activity of MRP1. MRP1
contains 25 cysteine residues but which, if any, of
Fig. 4. E¡ect of pH on MRP1 ATPase activity and LTC4
transport activity. (A) The ATPase activity of puri¢ed and re-
constituted MRP1 (1 Wg) was measured in bu¡er containing 2.5
mM ATP and 5 mM MgCl2 at the indicated pH as described
in Section 2. Values shown are the means of results obtained
in two independent experiments. (B) The ATP-dependent
[3H]LTC4 transport activity by membrane vesicles derived from
MRP1-transfected HeLa cells (T5) was measured at the indi-
cated pH values as described in Section 2. Data points repre-
sent mean values ( þ S.D.) of three determinations.
Fig. 3. E¡ect of ATP concentrations on MRP1 ATPase activ-
ity. The ATPase activity of MRP1 proteoliposomes was meas-
ured at various concentrations of ATP by incubation for 4 h at
37‡C in bu¡er containing 50 mM Tris-HCl, pH 7.4 and 5 mM
MgCl2. The Km for ATP hydrolysis was 104 þ 22 WM, as deter-
mined from regression analysis of the Lineweaver-Burk plot (in-
set). Data points represent mean values ( þ S.E.) of three inde-
pendent determinations.
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these is important for the function of the protein has
not been established [38].
3.3. E¡ect of inhibitors on MRP1 ATPase activity
The e¡ects of compounds known to inhibit other
ATPases were examined and the results are summar-
ized in Table 1. The ATPase activity of MRP1 pro-
teoliposomes was inhibited by orthovanadate, indi-
cating that a coordinate phosphorus complex in the
MRP1 molecule likely exists during ATP hydrolysis.
The IC50 of vanadate was approximately 10 WM,
which is comparable to values previously reported
for P-glycoprotein [27,28] but is much higher than
the values typically reported for P-type ATPases
(50^500 nM) [39]. On the other hand, MRP1 ATPase
activity was relatively insensitive to NBD-C1 (IC50
50 WM) as are P-type ATPases and P-glycoprotein
(IC50 20 WM) [27]. NEM, a potent inhibitor of P-
glycoprotein [28] and V-type ATPases, was a rela-
tively weak inhibitor of MRP1 ATPase activity
(IC50 500 WM). This inhibition likely involves a re-
active sulfhydryl group since the addition of DTT
increased the IC50 of NEM to 1 mM. These values
are comparable to the concentration of NEM that
resulted in 70% inhibition of LTC4 uptake in
MRP1-enriched membrane vesicles [14].
MRP1 ATPase activity was also relatively insensi-
tive to azide and oligomycin, both potent inhibitors
of F1F0-ATPase [40,41], exhibiting IC50’s for these
compounds greater than 6 mM and 80 WM, respec-
tively. The Ca2-ATPase inhibitor, EGTA, half-max-
imally inhibited MRP1 ATPase activity at 0.5 mM
but complete inhibition was not observed even at a
concentration of 6 mM. Ouabain, a speci¢c inhibitor
of Na/K-ATPase [42] and ba¢lomycin A, a specif-
ic inhibitor of V-type ATPase [43], had no e¡ect on
MRP1 ATPase activity up to 6 mM. NaF, which is
an inhibitor of gastric H,K-ATPase [44], Ca2-
ATPase of the sarcoplasmic reticulum [45], and
Mg2-ATPase of human erythrocyte ghosts [46] as
well as several classes of phosphatases, half-maxi-
mally inhibited MRP1 ATPase activity at 1 mM.
Similarly, Al-Shawi and Senior [24] reported NaF
inhibited P-glycoprotein ATPase activity with an
IC50 of 3.3 mM. We also found that NaF inhibited
LTC4 transport by MRP1-enriched membrane
vesicles (data not shown).
3.4. pH dependence of MRP1 ATPase activity and
LTC4 transport
The pH pro¢le of the ATPase activity of MRP1
proteoliposomes is shown in Fig. 4A. Maximal ATP-
Fig. 5. Nucleotide speci¢city of MRP1 ATPase activity. The
rate of nucleotide hydrolysis by reconstituted MRP1 (1.5 Wg)
was measured in a reaction mixture containing 50 mM Tris-
HC1, pH 7.4, 2.5 mM nucleotides and 5 mM MgC12 as de-
scribed in Section 2. In the experiments shown, 100% control
activity was 9.2 þ 0.2 nmol min31 mg31 MRP1. Data points
represent mean values ( þ S.E.) of three independent experi-
ments.
Table 1
E¡ect of inhibitors on the ATPase activity of puri¢ed and re-
constituted MRP1
Inhibitor IC50 (WM)
Na3VO4 10
NBD-C1 50
NEM 500
NEM +1 mM DTT 1 000
NaN3 s 6 000
Oligomycin s 80a
EGTA 500
Ba¢lomycin A1 s 10
Ouabain s 6 000
NaF 1 000
MRP1 proteoliposomes were incubated with various concentra-
tions of inhibitors for 30 min at room temperature in bu¡er
containing 50 mM Tris-HCl, pH 7.4 and 5 mM MgCl2 prior to
addition of ATP (2.5 mM). ATPase activity was measured and
IC50 values calculated as described in Section 2.
aConcentration of oligomycin is approximate and based on a
presumed average molecular weight of 790.
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ase activity was observed at pH 7.5^8.0, which is
similar to that of P-glycoprotein [25,27]. For com-
parison, the pH dependence of LTC4 transport by
T5 membrane vesicles was performed and the results
are shown in Fig. 4B. The optimal pH for LTC4
transport was between 8 and 9, which is slightly
higher than the pH value for maximal MRP1 ATP-
ase activity. Thus MRP1 appears to have optimal
activities for both ATP hydrolysis and substrate
transport in a slightly basic environment.
3.5. Nucleotide speci¢city of MRP1
To establish the nucleotide dependence of recon-
stituted native MRP1, various nucleotide triphos-
phates and diphosphates were substituted for ATP.
Fig. 5 shows that puri¢ed and reconstituted MRP1
was able to hydrolyze a range of nucleotides. dATP,
GTP, UTP and ITP were all good MRP1 substrates
with rates of hydrolysis similar to that of ATP. The
highest rate of hydrolysis was observed for CTP,
which was nearly twice that for ATP. ADP and
GDP were also hydrolyzed at a rate of hydrolysis
that was 50% or less of that for ATP. Thus, like
other ABC transporter proteins [27], MRP1 has a
broad nucleotide speci¢city.
3.6. MRP1 ATPase activity is stimulated by its
substrates
Stimulation of P-glycoprotein ATPase activity by
many of its substrates, including chemotherapeutic
Fig. 6. E¡ect of organic anions and S-decyl-GSH on MRP1 ATPase activity. The ATPase activity of MRP1 proteoliposomes was as-
sayed in a reaction mixture containing 50 mM Tris-HCl, pH 7.4, 2.5 mM ATP, 5 mM MgCl2 and di¡erent concentrations of various
conjugated organic anions. (A) LTC4 ; (B) E217LG; (C) GSSG; and (D) S-decyl-GSH. In the case of E217LG (B), the assay mixture
was supplemented with 17L-estradiol 3-(L-D-glucuronide) (20 WM). In the experiments shown, 100% control activities were 5^10 nmol
min31 mg31 MRP1. Data points represent mean values ( þ S.E.) of three independent experiments.
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agents, has been reported by numerous investigators
[23^28]. Consequently, it was of interest to determine
whether known MRP1 substrates and the drugs to
which MRP1 confers resistance a¡ected its ATPase
activity in a similar manner. As shown in Fig. 6A,
the ATPase activity of puri¢ed and reconstituted
MRP1 was maximally stimulated 30% by LTC4, a
high a⁄nity substrate of MRP1 [11,13,14]. Half-
maximal stimulation by LTC4 was observed at ap-
proximately 150 nM, which is comparable to the Km
(LTC4) (70^100 nM) obtained in transport studies
with MRP1-enriched membrane vesicles [11,13,14].
E217LG is also transported by MRP1 in mem-
brane vesicles [18,19] but unexpectedly, this com-
pound caused moderate inhibition of MRP1 ATPase
activity over the concentration range 1^15 WM. At 15
WM E217LG, MRP1 ATPase activity was decreased
by 10^20% and the extent of inhibition did not in-
crease with higher E217LG concentrations up to 100
WM (not shown). Because of the potential of the lipid
environment to a¡ect the ATPase activity of MRP1,
we considered the possibility that the inhibition
could be the consequence of a non-speci¢c e¡ect of
the relatively lipophilic steroid glucuronide on pro-
teoliposome structure. In agreement with this sugges-
tion, we found that the structural isomer 17L-estra-
diol 3-(L-D-glucuronide) which we have shown
previously does not compete for E217LG transport
by MRP1 [19], was also inhibitory (not shown). To
investigate the possibility that the non-speci¢c inhib-
ition by estrogen glucuronide had obscured a stimu-
lation of ATPase activity, we repeated the experi-
ments with E217LG in the presence of 20 WM 17L-
estradiol 3-(L-D-glucuronide), a concentration at
which non-speci¢c inhibition was maximal. Under
these conditions, the addition of 1^5 WM E217LG
stimulated ATPase activity in a concentration de-
pendent manner up to a maximal 40% increase
(Fig. 6B). Additional 17L-estradiol 3-(L-D-glucuro-
nide) in the same concentration range had no e¡ect.
The concentration of E217LG that resulted in 50%
maximal stimulation was 1.6 WM which is similar to
the Km for this compound determined by transport
studies with MRP1-enriched membrane vesicles
[18,19].
GSSG, also a substrate of MRP1 [16,17], stimu-
lated ATPase activity 50% at 1 mM (Fig. 6C). In
addition, MRP1 ATPase activity was stimulated by
GSH (not shown). However, this stimulation by
GSH was likely the result of the presence of small
amounts of GSSG formed during the relatively long
ATPase assay time of 4 h. In support of this inter-
pretation, GSH did not signi¢cantly stimulate
ATPase activity in the presence of 5 mM DTT (not
shown). S-decyl-GSH, which has been previously
shown to be a potent competitive inhibitor of
MRP1-mediated LTC4 transport activity [13,14],
had no e¡ect on MRP1 ATPase activity (Fig. 6D).
The chemotherapeutic agents vincristine, VP-16 and
daunorubicin were tested at concentrations of 30^100
WM. None of these compounds detectably stimulated
MRP1 ATPase activity, either in the presence or ab-
sence of 2 mM GSH (data not shown). Verapamil, a
potent stimulator of P-glycoprotein ATPase activity
and reversing agent of P-glycoprotein-mediated re-
sistance also had no e¡ect on MRP1 ATPase activity
(data not shown)
4. Discussion
In the present study, we describe a simple proce-
dure for puri¢cation of native MRP1 from multidrug
resistant H69AR lung cancer cells. This procedure is
comprised of a di¡erential two-step CHAPS solubi-
lization of MRP1 from plasma membranes followed
by immunoa⁄nity chromatography using the human
MRP1-speci¢c mAb QCRL-1. MAb QCRL-1 has
been well characterized and shown to recognize a
human MRP1-speci¢c heptapeptide epitope in the
linker region which connects the two halves of the
protein [30,31]. Using this method, MRP1 of approx-
imately 80% purity as judged by silver staining was
obtained with a total recovery of more than 80%. We
estimate that MRP1 accounts for approximately 5%
of total proteins in the plasma membranes isolated
from H69AR cells, consistent with the high levels of
drug resistance in these cells [32].
When puri¢ed MRP1 from H69AR cells was re-
constituted into proteoliposomes by rapid dilution,
relatively low levels of ATPase activity were detect-
able. Puri¢ed recombinant histidine-tagged MRP1 as
judged by Coomassie Blue staining was recently re-
ported to possess high constitutive ATPase activity
(460 nmol mg31 min31) comparable to that of P-
glycoprotein [47]. However, in our studies, puri¢ed
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and reconstituted native MRP1 showed a basal ATP-
ase activity of 5^10 nmol min31 mg31. This activity
is 60^100-fold lower than that of P-glycoprotein [23^
28]. In this regard, it is interesting to note that the
MRP1-related yeast protein Yor1p exhibits ATPase
activity that is at least 15-fold lower than that of the
P-glycoprotein-related yeast protein Pdr5p [48]. Oth-
er reconstituted ABC transporters with relatively low
levels of basal ATPase activity include CFTR (50
nmol min31 mg31) [49,50] and the recently described
ABCR (1.3 nmol min31 mg31), a protein involved in
early onset macular degeneration [51].
The possibility that MRP1 may lose some of its
activity during the immunoa⁄nity puri¢cation and
reconstitution procedures cannot presently be ex-
cluded. It is also possible that the reconstitution sys-
tem used in this study is not optimal for MRP1.
Integral membrane proteins, including P-glycopro-
tein, usually require speci¢c lipids for optimal activ-
ity and may be inhibited by other lipid species. Their
activities are also sensitive to the lipid bilayer dynam-
ics and physico-chemical state [52^55]. Preliminary
experiments indicate that the activity of MRP1 is
also modulated signi¢cantly by changes in its lipid
environment (unpublished observation). Neverthe-
less, the relatively low level ATPase activity of recon-
stituted native MRP1 reported here is consistent with
the level of ATPase activity attributable to MRP1 in
membrane vesicles [29] (unpublished observation).
Taken together, these results suggest that MRP1
has a low intrinsic ATPase activity. It is important
to note, however, that the dependence of the activity
of the reconstituted native MRP1 on ATP concen-
tration [Km (ATP) 104 WM] is comparable to that
obtained from transport studies with MRP1-enriched
membrane vesicles [12,13,16,17]. In contrast, the af-
¢nity reported for puri¢ed histidine-tagged recombi-
nant MRP1 solubilized in n-dodecyl-L-D-maltoside
[Km (ATP) 3 mM] is markedly lower, for reasons
which are presently not understood [47].
The comparatively low ATPase activity of recon-
stituted native MRP1 from H69AR cells and its rel-
atively high a⁄nity for this nucleotide may be linked
to the structural di¡erences between the two NBDs
of MRP1 and its related proteins and those of the
P-glycoproteins. The NH2- and COOH-proximal
NBDs of the P-glycoproteins are quite similar, and
although cooperativity between the two domains is
required for activity, they appear to be functionally
quite similar although not necessarily equivalent [56^
58]. In contrast, the two NBDs of MRP1 and its
related proteins as well as CFTR are considerably
less similar to each other [1^4]. In the case of
CFTR, there is convincing evidence that the two
NBDs are functionally distinct [59,60]. There are
13 amino acids present in the NBDs of the P-glyco-
proteins that are absent from the comparable loca-
tion in the ¢rst NBD of the MRP1-related proteins
and CFTR [3,4]. The absence of these amino acids
signi¢cantly shortens the distance between the
Walker A and B motifs and is known to a¡ect the
folding of this domain [61]. Furthermore, the
ABC ‘active transport family’ signature (LSSG-
GQX3RHydXHydA), which is relatively invariant
in both NBDs of the P-glycoproteins, is highly con-
served in the ¢rst NBD, but not in the second NBD
of CFTR and the MRP1-related proteins [4]. Thus it
would not be surprising if the structural character-
istics of the two NBDs common to MRP1-related
proteins had important consequences with respect
to the mechanism of ATP binding and hydrolysis
and possibly for the coupling between ATP hydro-
lysis and substrate transport as well.
To further characterize the ATPase activity of re-
constituted MRP1 and to distinguish it from that of
other possible contaminating ATPases, the e¡ects of
several inhibitors were examined (Table 1). The pres-
ence of contaminating vacuolar, or V-type, ATPases
could be excluded based on the observation that the
MRP1 ATPase activity was relatively sensitive to
vanadate but insensitive to N-ethylmaleimide,
NBD-C1 and ba¢lomycin A1. In contrast, P-glyco-
protein ATPase activity is sensitive to N-ethylmalei-
mide and ba¢lomycin A1 [28,62]. The concentration
of vanadate required for 50% inhibition (10 WM) of
MRP1 ATPase activity is much higher than that
typically required to inhibit P-type ATPases [39],
although it is similar to that required to inhibit P-
glycoprotein ATPase activity [28]. Contamination
with Na/K-ATPase, a highly abundant P-type
ATPase, could be excluded based on the insensitivity
of MRP1 ATPase activity to ouabain. The insensi-
tivity of MRP1 ATPase activity to sodium azide and
oligomycin indicates that typical F1F0-ATPases may
also be excluded as possible contaminants. In con-
trast, P-glycoprotein ATPase activity, although in-
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sensitive to azide, is quite sensitive to oligomycin
[24]. Taken together, these results indicate that con-
tributions to the observed MRP1 ATPase activity by
contaminating typical P-, F-, and V-type ATPases
may be excluded. They also indicate that the
MRP1 ATPase activity does not share a common
ATPase inhibitor pro¢le with P-glycoprotein.
The ATPase activity of MRP1 was stimulated by
several compounds known from previous studies to
be substrates for this transport protein. LTC4 has the
highest known a⁄nity for MRP1 and this compound
stimulated ATPase activity approximately 30%
above basal activity. Presuming that substrate stim-
ulation of ATPase activity is the driving force of
substrate translocation, then 1.5^3 nmol min31
mg31 MRP1 of ATP hydrolysis would contribute
to LTC4 transport by MRP1. Previous studies of
MRP1-enriched membrane vesicles isolated from
H69AR cells [14], indicated that the speci¢c LTC4
transport activity of MRP1 was approximately
100^300 pmol min31 mg31 protein. Since MRP1
comprises approximately 5% of total plasma mem-
brane protein in H69AR cells, LTC4 transport activ-
ity may be estimated to be approximately 2^6 nmol
min31 mg31 MRP1. This implies a stoichiometry of
molecules LTC4 transported to molecules ATP hy-
drolyzed of 1^2, which in turn suggests a mechanism
for substrate translocation by MRP1 that is tightly
coupled to ATP hydrolysis. Similarly, on the basis of
the greater than 10-fold di¡erence in their ATPase
activities, it was suggested that the MRP1-related
Yor1 yeast protein is a more highly coupled trans-
porter than the P-glycoprotein-related Pdr5p yeast
protein [48].
Reconstituted MRP1 ATPase activity from
H69AR cells was stimulated by LTC4 in a linear
manner with respect to substrate concentration with
maximal stimulation at approximately 250 nM and
half-maximal stimulation at approximately 150 nM.
These values are consistent with the Km (LTC4) (70^
100 nM) obtained in transport studies with MRP1-
enriched membrane vesicles [11,14]. In contrast, stim-
ulation of the recombinant histidine-tagged MRP1
by LTC4 showed no concentration dependence over
a 1000-fold range (1 to 1000 nM) and maximal stim-
ulation required a concentration of at least 10 WM
[47]. The basis for this di¡erence in potency between
the two preparations of MRP1 is unclear.
The observation that GSSG but not GSH stimu-
lated MRP1 ATPase activity is consistent with the
ability of GSSG to be transported by MRP1 [16,20].
GSH itself is not a substrate but may be co-trans-
ported with the Vinca alkaloid vincristine [20,21].
The alkyl derivative S-decyl-GSH also did not sig-
ni¢cantly stimulate MRP1 ATPase activity although
it is a competitive inhibitor of LTC4 transport in
MRP1-enriched membrane vesicles [14]. These obser-
vations suggest that S-decyl-GSH may interact with
MRP1 at the same site as GSH but is not itself trans-
ported and thus it can compete e¡ectively with GSH
for transport.
In contrast to our inability to demonstrate stimu-
lation of reconstituted MRP1 ATPase activity by
anticancer drugs, Chang et al. [47] reported that dau-
norubicin, doxorubicin, colchicine, vinblastine and
vincristine all moderately stimulated the ATPase ac-
tivity of histidine-tagged recombinant MRP1. The
concentration dependence of this stimulation was
comparable for all ¢ve drugs from 0.1^500 WM.
This ¢nding is somewhat surprising given that these
compounds are not transported by MRP1 in mem-
brane vesicles and cells overexpressing MRP1 typi-
cally display very low levels of resistance to colchi-
cine and vinblastine compared to vincristine,
doxorubicin and daunorubicin [1,14,16,20,21]. The
basis for the apparent discrepancy between our ¢nd-
ings and those reported previously is unknown. Un-
like membrane vesicle studies where MRP1-mediated
transport of vincristine and daunorubicin may be
stimulated by physiological concentrations of GSH
[14,20,21], we found that addition of 2 mM GSH
did not enhance the ability of these drugs to stimu-
late MRP1 ATPase activity. The intrinsically low
levels of MRP1 ATPase activity may make detection
of stimulation by these drugs di⁄cult, particularly
since previous studies have shown that the e⁄ciency
with which MRP1 transports or is inhibited by un-
modi¢ed compounds is considerably lower than for
their conjugated derivatives [15,18,63]. It should also
be noted that in the case of P-glycoprotein, not all
substrates stimulate activity and in some cases, inhib-
ition rather than stimulation has been observed
[26,36,62]. Whether this is also true of MRP1 re-
mains to be determined. Alternatively, the lipids
used to reconstitute MRP1 in this study might not
be optimal for observation of MRP1 activation by
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these substrates. Like P-glycoprotein [26,53^55,64],
the lipid environment in which MRP1 is reconsti-
tuted is likely to markedly a¡ect the interaction be-
tween drugs and MRP1 and thus modulate the de-
gree of drug stimulation of ATPase activity. This
possibility is the subject of ongoing investigations.
In summary, we have puri¢ed native MRP1 and
reconstituted it into proteoliposomes. The reconsti-
tuted MRP1 showed low level ATPase activity which
could be stimulated by its conjugated organic anion
substrates LTC4 and E217LG at concentrations that
correspond well with Km values reported previously
from transport studies with MRP1-enriched mem-
brane vesicles. ATPase inhibitor experiments clearly
distinguished MRP1 ATPase activity from that of
other ATPases, including P-glycoprotein. A tight
coupling mechanism between ATP hydrolysis and
translocation of substrate is proposed for MRP1
based on the results obtained. These studies represent
the ¢rst characterization of the ATPase activity of
reconstituted native MRP1. The simple immunoa⁄n-
ity puri¢cation procedure described will facilitate
mechanistic studies of ATP dependent MRP1-medi-
ated conjugated organic anion and drug transport.
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